Why BioNTech Ended Its BNT122 Colorectal Cancer Vaccine Trial

BioNTech has ended BNT122-01, a Phase 2 trial of its individualized mRNA cancer immunotherapy autogene cevumeran, after an independent Data Safety Monitoring Board (DSMB) determined that continuing the study was unlikely to change its efficacy outcome. The board identified a numerical imbalance in overall survival between the treatment and control arms, but reported no new safety signal. 517

The decision is a clear setback for BioNTech’s colorectal-cancer program. It is not, on the available evidence, a definitive verdict on every use of individualized neoantigen mRNA therapy.

What the BNT122-01 trial tested

BNT122-01 evaluated autogene cevumeran, also known as BNT122 or RO7198457, as an adjuvant monotherapy after surgery in patients with circulating tumor DNA (ctDNA)-positive, high-risk Stage II or Stage III colorectal cancer. The comparator was watchful waiting. BioNTech developed the candidate with Genentech, part of the Roche Group. 512

The trial focused on patients whose tumors had been surgically resected but whose detectable ctDNA indicated a higher risk of residual disease. That design sought to use a patient-specific vaccine to train immune responses against neoantigens—mutations found in an individual patient’s tumor.

Why the study was stopped

The trial’s futility boundary was first crossed in October 2025. At that point, the DSMB judged the available data and follow-up too immature to make a reliable efficacy assessment, so the study continued without a safety-related modification.

After a later review, the DSMB reached a different conclusion: the numerical overall-survival imbalance between the arms made it unlikely that additional follow-up would materially change the efficacy outcome. It recommended discontinuing treatment and terminating the trial, and BioNTech announced that it would follow the recommendation. 517

“Futility” does not necessarily mean that the treatment caused a quantified increase in deaths. BioNTech has not disclosed the size or direction of the overall-survival imbalance in the information provided here. The responsible conclusion is therefore that the trial was stopped because it was not expected to demonstrate the intended efficacy—not that the available announcement establishes a specific level of harm.

No new safety signal was reported

The DSMB did not identify new safety signals as the reason for ending BNT122-01. The decisive issue was the expected efficacy outcome. BioNTech said it would conduct a thorough analysis, including examining whether patient selection could help explain or inform the result, and share the findings with the scientific and medical community at an appropriate time. 5

That future analysis matters because a negative result in a biomarker-selected population can reflect several possibilities: insufficient immune activity, the limits of vaccine monotherapy, the biology of colorectal cancer, or a patient-selection strategy that did not identify the patients most likely to benefit. The announcement alone cannot distinguish among them.

How investors treated the news

The termination produced a negative read-through for mRNA oncology. BioNTech shares fell about 8% in morning trading, according to Investing.com, while another market report described a decline of roughly 8% and a fall of about 6% for Moderna; Pfizer was broadly unchanged. 9

The market reaction suggests that investors viewed the announcement as more than a single-study disappointment, but not as evidence of a broad pharmaceutical-sector shock. BioNTech had the most direct exposure to the failed trial, while Moderna was affected by the wider mRNA-cancer-vaccine narrative. Pfizer’s relative stability reinforced the impression that the sell-off was concentrated in the mRNA and oncology themes rather than the entire drug sector.

Why the result does not directly invalidate Moderna and Merck’s melanoma program

The comparison with Moderna and Merck’s personalized vaccine program needs to account for differences in both tumor type and treatment design.

Melanoma and colorectal cancer are different test environments

The colorectal-cancer study tested a difficult setting for immunotherapy. Colorectal tumors are often described as immunologically “cold,” although important subgroups—such as tumors with particular molecular features—can respond differently. By contrast, melanoma has traditionally been considered more immunogenic and is an established setting for immune checkpoint therapy. 3

That difference means a failed colorectal-cancer monotherapy study cannot be cleanly extrapolated to melanoma. It also means the result should not be dismissed as irrelevant: it is evidence that the approach did not establish efficacy in this specific colorectal-cancer population and treatment design.

The treatment combinations were not the same

BioNTech tested autogene cevumeran alone in BNT122-01. Moderna and Merck’s program combines intismeran autogene—also known as V940 or mRNA-4157—with pembrolizumab, marketed as Keytruda. 5

A checkpoint inhibitor can remove or reduce immune suppression, while a personalized vaccine is intended to help direct T-cell activity toward tumor-specific targets. The combination therefore tests a different biological hypothesis from vaccine monotherapy: not simply whether the vaccine can generate an immune response, but whether it can add clinical benefit when checkpoint blockade is already active.

The melanoma results are positive, but not universal proof

Merck and Moderna reported that the Phase 3 INTerpath-001 trial met its recurrence-free-survival and distant-metastasis-free-survival endpoints in patients with completely resected Stage IIB–IV melanoma receiving intismeran autogene plus Keytruda.

Those results support the vaccine-plus-checkpoint strategy in that melanoma population. They do not prove that individualized mRNA vaccines work across all tumor types, or that monotherapy will work in colorectal cancer. The fairest interpretation is that the field now has a positive late-stage signal in one combination and tumor context alongside a negative mid-stage result in another.

What remains in BioNTech’s pipeline

The BNT122-01 termination does not end BioNTech’s broader work on autogene cevumeran. The company’s pipeline includes IMcode003, a Phase 2 study evaluating the candidate with checkpoint inhibition and chemotherapy in resected pancreatic ductal adenocarcinoma. 11

That program is especially relevant to interpretation because it uses a combination regimen rather than the colorectal trial’s monotherapy design. Earlier investigator-initiated pancreatic-cancer follow-up also reported persistent T-cell responses in some patients, but those findings came from a small Phase 1 study and should not be treated as proof of clinical efficacy. 14

BioNTech also has BNT113, an HPV16-targeting mRNA cancer immunotherapy being evaluated in head and neck cancer, with an interim analysis listed among its expected 2026 oncology readouts. 13 Results from that program and planned ESMO Congress data will provide separate evidence about whether immune-target selection and combination treatment can improve outcomes in other cancers.

Financial capacity changes the question, not the clinical result

BioNTech reported €16.6 billion in cash, cash equivalents, and security investments as of June 30, 2026.

That balance gives the company financial flexibility to continue funding multiple oncology programs after a failed trial. It does not make BNT122-01’s result less important, but it reduces the likelihood that one termination alone will force an immediate retreat from the broader oncology strategy.

The next phase of evaluation should focus less on whether individualized neoantigen mRNA therapy “works” in the abstract and more on three practical questions:

1. Which tumor types are sufficiently immunogenic for the approach?
2. Which biomarkers and patient-selection methods identify likely responders?
3. When does the vaccine need to be paired with checkpoint inhibition or another immune-modulating treatment?

BNT122-01 answers one narrow but important version of those questions: in ctDNA-positive, surgically resected high-risk colorectal cancer, autogene cevumeran monotherapy was judged futile before the study could deliver a favorable efficacy result. The pancreatic, head-and-neck, and other combination programs will determine how broadly that lesson applies.